Abstract
Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are immune-mediated cholangiopathies with enigmatic etiology and pathogenesis. They have distinct clinical, laboratory, immunological, and histomorphological characteristics. Well-characterized animal models for PBC and PSC are utterly needed to develop novel pathogenetic concepts and to study innovative treatment strategies. The aim of the current paper is to outline the characteristics of ideal PBC and PSC animal models and to contrast this with a real-life up-to-date overview of currently available mouse models. Although some of this models show several individual characteristics of PBC and PSC, it is obvious that all of them have substantial and important limitations. Nevertheless, some may be beneficial to study certain pathophysiological aspects. Potential cholangiopathy animal models should be systematically investigated in regard to elevated serum alkaline phosphatase, bilirubin, and bile acid levels; immunological abnormalities; and longitudinal studies in regard to their liver phenotype. We herein propose a common systematic workup for potential models based on the fact that there are some intriguing disease combinations in specific genetically modified mice and recommend a stepwise process in regard to model characterization with methodical harvesting and screening of numerous organs for potential concomitant diseases. Due to the complex nature of both cholangiopathies, it seems to be very likely that no single perfect PBC or PSC model will ever be generated. The models outlined herein will certainly help to clarify specific pathogenetic aspects and even more important may turn out to be suitable to test potential drugs for treatment.
Similar content being viewed by others
References
Loftus EV Jr, Harewood GC, Loftus CG, Tremaine WJ, Harmsen WS, Zinsmeister AR et al (2005) PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 54:91–96
Broome U, Olsson R, Lööf L, Bodemar G, Hultcrantz R, Danielsson A et al (1996) Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 38:610–615
Fausa O, Schrumpf E, Elgjo K (1991) Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis 11:31–39
Hirschfield GM, Gershwin ME (2013) The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol 24:303–330
Hirschfield GM (2011) Diagnosis of primary biliary cirrhosis. Best Pract Res Clin Gastroenterol 25:701–712
Hirschfield GM, Gershwin ME (2011) Primary biliary cirrhosis: one disease with many faces. Isr Med Assoc J 13:55–59
Hirschfield GM, Heathcote EJ, Gershwin ME (2010) Pathogenesis of cholestatic liver disease and therapeutic approaches. Gastroenterology 139:1481–1496
Hohenester S, Oude-Elferink RP, Beuers U (2009) Primary biliary cirrhosis. Semin Immunopathol 31:283–307
Hirschfield GM, Liu X, Xu C, Lu Y, Xie G, Lu Y et al (2009) Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med 360:2544–2555
Weismüller TJ, Wedemeyer J, Kubicka S, Strassburg CP, Manns MP (2008) The challenges in primary sclerosing cholangitis—aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol 1:S38–S57
Karlsen TH, Schrumpf E, Boberg KM (2010) Update on primary sclerosing cholangitis. Dig Liver Dis 42:390–400
Vierling JM (2001) Animal models for primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 15:591–610
Edwards DF, McCracken MD, Richardson DC (1983) Sclerosing cholangitis in a cat. J Am Vet Med Assoc 182:710–712
Nakayama H, Uchida K, Lee SK, Uetsuka K, Hasegawa A, Goto N (1992) Three cases of feline sclerosing lymphocytic cholangitis. J Vet Med Sci 54:769–771
Arenas-Gamboa AM, Bearss JJ, Hubbard GB, Porter BF, Owston MA, Dick EJ Jr (2012) Sclerosing cholangitis in baboons (Papio spp) resembling primary sclerosing cholangitis of humans. Vet Pathol 49:524–527
Garrett WS, Gallini CA, Yatsunenko T, Michaud M, DuBois A, Delaney ML, Punit S et al (2010) Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis. Cell Host Microbe 8:292–300
Kaser A, Lee AH, Franke A, Glickman JN, Zeissig S, Tilg H, Nieuwenhuis EE et al (2008) XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell 134:743–756
Oertelt S, Lian ZX, Cheng CM, Chuang YH, Padgett KA, He XS et al (2006) Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice. J Immunol 177:1655–1660
Yang GX, Lian ZX, Chuang YH, Moritoki Y, Lan RY, Wakabayashi K et al (2008) Adoptive transfer of CD8(+) T cells from transforming growth factor beta receptor type II (dominant negative form) induces autoimmune cholangitis in mice. Hepatology 47:1974–1982
Moritoki Y, Zhang W, Tsuneyama K, Yoshida K, Wakabayashi K, Yang GX et al (2009) B cells suppress the inflammatory response in a mouse model of primary biliary cirrhosis. Gastroenterology 136:1037–1047
Chuang YH, Lian ZX, Yang GX, Shu SA, Moritoki Y, Ridgway WM et al (2008) Natural killer T cells exacerbate liver injury in a transforming growth factor beta receptor II dominant-negative mouse model of primary biliary cirrhosis. Hepatology 47:571–580
Tsuda M, Zhang W, Yang GX, Tsuneyama K, Ando Y, Kawata K et al (2013) Deletion of interleukin (IL)-12p35 induces liver fibrosis in dominant-negative TGFβ receptor type II mice. Hepatology 57:806–816
Wakabayashi K, Lian ZX, Moritoki Y, Lan RY, Tsuneyama K, Chuang YH et al (2006) IL-2 receptor alpha(−/−) mice and the development of primary biliary cirrhosis. Hepatology 44:1240–1249
Hsu W, Zhang W, Tsuneyama K, Moritoki Y, Ridgway WM, Ansari AA et al (2009) Differential mechanisms in the pathogenesis of autoimmune cholangitis versus inflammatory bowel disease in interleukin-2Ralpha(−/−) mice. Hepatology 49:133–140
Yao Y, Yang W, Yang YQ, Ma HD, Lu FT, Li L et al (2014) Distinct from its canonical effects, deletion of IL-12p40 induces cholangitis and fibrosis in interleukin-2Rα(−/−) mice. J Autoimmun 51:99–108
Irie J, Wu Y, Wicker LS, Rainbow D, Nalesnik MA, Hirsch R et al (2006) NOD.c3c4 congenic mice develop autoimmune biliary disease that serologically and pathogenetically models human primary biliary cirrhosis. Exp Med 203:1209–1219
Nakagome Y, Ueno Y, Kogure T, Fukushima K, Moritoki Y, Ridgway WM et al (2007) Autoimmune cholangitis in NOD.c3c4 mice is associated with cholangiocyte-specific Fas antigen deficiency. J Autoimmun 29:20–29
Moritoki Y, Tsuda M, Tsuneyama K, Zhang W, Yoshida K, Lian ZX et al (2011) B cells promote hepatic inflammation, biliary cyst formation, and salivary gland inflammation in the NOD.c3c4 model of autoimmune cholangitis. Cell Immunol 268:16–23
Salas JT, Banales JM, Sarvide S, Recalde S, Ferrer A, Uriarte I et al (2008) Ae2a, b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis. Gastroenterology 134:1482–1493
Zhang W, Sharma R, Ju ST, He XS, Tao Y, Tsuneyama K et al (2009) Deficiency in regulatory T cells results in development of antimitochondrial antibodies and autoimmune cholangitis. Hepatology 49:545–552
Tsuneyama K, Nose M, Nisihara M, Katayanagi K, Harada K, Nakanuma Y (2001) Spontaneous occurrence of chronic non-suppurative destructive cholangitis and antimitochondrial autoantibodies in MRL/lpr mice: possible animal model for primary biliary cirrhosis. Pathol Int 51:418–424
Ohba K, Omagari K, Murase K, Hazama H, Masuda J, Kinoshita H et al (2002) A possible mouse model for spontaneous cholangitis: serological and histological characteristics of MRL/lpr mice. Pathology 34:250–256
Masanaga T, Watanabe Y, Van de Water J, Leung PS, Nakanishi T, Kajiyama G et al (1998) Induction and persistence of immune-mediated cholangiohepatitis in neonatally thymectomized mice. Clin Immunol Immunopathol 89:141–149
Aisaka Y, Watanabe Y, Kamiyasu M, Masanaga T, Tsuji K, Nakanishi T et al (2000) Immune-mediated cholangiohepatitis in neonatally thymectomized mice: the role of T cells and analysis of T-cell receptor Vbeta usage. J Autoimmun 14:239–246
Wakabayashi K, Lian ZX, Leung PS, Moritoki Y, Tsuneyama K, Kurth MJ et al (2008) Loss of tolerance in C57BL/6 mice to the autoantigen E2 subunit of pyruvate dehydrogenase by a xenobiotic with ensuing biliary ductular disease. Hepatology 48:531–540
Wakabayashi K, Yoshida K, Leung PS, Moritoki Y, Yang GX, Tsuneyama K et al (2009) Induction of autoimmune cholangitis in non-obese diabetic (NOD).1101 mice following a chemical xenobiotic immunization. Clin Exp Immunol 155:577–586
Dhirapong A, Lleo A, Yang GX, Tsuneyama K, Dunn R, Kehry M et al (2011) B cell depletion therapy exacerbates murine primary biliary cirrhosis. Hepatology 53:527–535
Wu SJ, Yang YH, Tsuneyama K, Leung PS, Illarionov P, Gershwin ME et al (2011) Innate immunity and primary biliary cirrhosis: activated invariant natural killer T cells exacerbate murine autoimmune cholangitis and fibrosis. Hepatology 53:915–925
Ambrosini YM, Yang GX, Zhang W, Tsuda M, Shu S, Tsuneyama K et al (2011) The multi-hit hypothesis of primary biliary cirrhosis: polyinosinic-polycytidylic acid (poly I:C) and murine autoimmune cholangitis. Clin Exp Immunol 166:110–120
Ide T, Sata M, Suzuki H, Uchimura Y, Murashima S, Shirachi M et al (1996) An experimental animal model of primary biliary cirrhosis induced by lipopolysaccharide and pyruvate dehydrogenase. Kurume Med J 43:185–188
Mattner J, Savage PB, Leung P, Oertelt SS, Wang V, Trivedi O et al (2008) Liver autoimmunity triggered by microbial activation of natural killer T cells. Cell Host Microbe 3:304–315
Wang J, Shan Y, Jiang Z, Feng J, Li C, Ma L et al (2013) High frequencies of activated B cells and T follicular helper cells are correlated with disease activity in patients with new-onset rheumatoid arthritis. Clin Exp Immunol 174:212–220
Koarada S, Wu Y, Fertig N, Sass DA, Nalesnik M, Todd JA et al (2004) Genetic control of autoimmunity: protection from diabetes, but spontaneous autoimmune biliary disease in a nonobese diabetic congenic strain. J Immunol 173:2315–2323
Melero S, Spirlì C, Zsembery A, Medina JF, Joplin RE, Duner E et al (2002) Defective regulation of cholangiocyte Cl−/HCO3 (−) and Na+/H+ exchanger activities in primary biliary cirrhosis. Hepatology 35:1513–1521
Prieto J, García N, Martí-Climent JM, Peñuelas I, Richter JA, Medina JF (1999) Assessment of biliary bicarbonate secretion in humans by positron emission tomography. Gastroenterology 117:167–172
Medina JF, Martínez-Ansó VJJ, Prieto J (1997) Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis. Hepatology 25:12–17
Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA et al (2001) Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 27:68–73
Amano K, Leung PS, Rieger R, Quan C, Wang X, Marik J et al (2005) Chemical xenobiotics and mitochondrial autoantigens in primary biliary cirrhosis: identification of antibodies against a common environmental, cosmetic, and food additive, 2-octynoic acid. J Immunol 174:5874–5883
Leung PS, Park O, Tsuneyama K, Kurth MJ, Lam KS, Ansari AA et al (2007) Induction of primary biliary cirrhosis in guinea pigs following chemical xenobiotic immunization. J Immunol 179:2651–2657
Pollheimer MJ, Trauner M, Fickert P (2011) Will we ever model PSC?—"it's hard to be a PSC model!". Clin Res Hepatol Gastroenterol 35:792–804
Mourelle M, Salas A, Vilaseca J, Guarner F, Malagelada JR (1995) Induction of chronic cholangitis in the rat by trinitrobenzenesulfonic acid. J Hepatol 22:219–225
Orth T, Neurath M, Schirmacher P, Galle PR, Mayet WJ (2000) A novel rat model of chronic fibrosing cholangitis induced by local administration of a hapten reagent into the dilated BD is associated with increased TNF-alpha production and autoantibodies. J Hepatol 33:862–872
Tjandra K, Sharkey KA, Swain MG (2000) Progressive development of a Th1-type hepatic cytokine profile in rats with experimental cholangitis. Hepatology 31:280–290
Fickert P, Stöger U, Fuchsbichler A, Moustafa T, Marschall HU, Weiglein AH et al (2007) A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis. Am J Pathol 171:525–536
Marzioni M, Saccomanno S, Agostinelli L, Rychlicki C, De Minicis S, Pierantonelli I et al (2013) PDX-1/Hes-1 interactions determine cholangiocyte proliferative response to injury in rodents: possible implications for sclerosing cholangitis. J Hepatol 58:750–756
Fickert P, Fuchsbichler A, Marschall HU, Wagner M, Zollner G, Krause R et al (2006) Lithocholic acid feeding induces segmental BD obstruction and destructive cholangitis in mice. Am J Pathol 168:410–422
Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Weiglein AH, Lammert F et al (2002) Ursodeoxycholic acid aggravates bile infarcts in BD-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 123:1238–1251
Fickert P, Fuchsbichler A, Wagner M, Zollner G, Kaser A, Tilg H et al (2004) Regurgitation of bile acids from leaky BDs causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 127:261–274
Popov Y, Patsenker E, Fickert P, Trauner M, Schuppan D et al (2005) Mdr2 (Abcb4)−/− mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol 43:1045–1054
Durie PR, Kent G, Phillips MJ, Ackerley CA (2004) Characteristic multiorgan pathology of cystic fibrosis in a long-living cystic fibrosis transmembrane regulator knockout murine model. Am J Pathol 164:1481–1493
Meerman L, Koopen NR, Bloks V, Van Goor H, Havinga R, Wolthers BG et al (1999) Biliary fibrosis associated with altered bile composition in a mouse model of erythropoietic protoporphyria. Gastroenterology 117:696–705
Libbrecht L, Meerman L, Kuipers F, Roskams T, Desmet V, Jansen P (2003) Liver pathology and hepatocarcinogenesis in a long-term mouse model of erythropoietic protoporphyria. J Pathol 199:191–200
Jochum W, David JP, Elliott C, Wutz A, Plenk H Jr, Matsuo K et al (2000) Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. Nat Med 6:980–984
Kireva T, Erhardt A, Tiegs G, Tilg H, Denk H, Haybaeck J et al (2011) Transcription factor Fra-1 induces cholangitis and liver fibrosis. Hepatology 53:1259–1269
Nakagawa H, Hikiba Y, Hirata Y, Font-Burgada J, Sakamoto K, Hayakawa Y et al (2014) Loss of liver E-cadherin induces sclerosing cholangitis and promotes carcinogenesis. Proc Natl Acad Sci U S A 111:1090–1095
Stephens J, Cosyns M, Jones M, Hayward A (1999) Liver and bile duct pathology following Cryptosporidium parvum infection of immunodeficient mice. Hepatology 30:27–35
Ungar BL, Burris JA, Quinn CA, Finkelman FD (1990) New mouse models for chronic Cryptosporidium infection in immunodeficient hosts. Infect Immun 58:961–969
Mead JR, Arrowood MJ, Sidwell RW, Healey MC (1991) Chronic Cryptosporidium parvum infections in congenitally immunodeficient SCID and nude mice. J Infect Dis 163:1297–1304
Ponnuraj EM, Hayward AR (2002) Requirement for TNF-Tnfrsf1 signalling for sclerosing cholangitis in mice chronically infected by Cryptosporidium parvum. Clin Exp Immunol 128:416–420
Ward JM, Anver MR, Haines DC, Benveniste RE (1994) Chronic active hepatitis in mice caused by Helicobacter hepaticus. Am J Pathol 145:959–968
Avenaud P, Le Bail B, Mayo K, Marais A, Fawaz R, Bioulac-Sage P et al (2003) Natural history of Helicobacter hepaticus infection in conventional A/J mice, with special reference to liver involvement. Infect Immun 71:3667–3672
Georgiev P, Jochum W, Heinrich S, Jang JH, Nocito A, Dahm F et al (2008) Characterization of time-related changes after experimental bile duct ligation. Br J Surg 95:646–656
Lichtman SN, Sartor RB (1991) Hepatobiliary injury associated with experimental small-bowel bacterial overgrowth in rats. Immunol Res 10:528–531
Lichtman SN, Wang J, Clark RL (1995) A microcholangiographic study of liver disease models in rats. Acad Radiol 2:515–521
Yamada S, Ishii M, Liang LS, Yamamoto T, Toyota T (1994) Small duct cholangitis induced by N-formyl L-methionine L-leucine L-tyrosine in rats. J Gastroenterol 29:631–636
Yamada S, Ishii M, Kisara N, Nagatomi R, Toyota T (1999) Macrophages are essential for lymphocyte infiltration in formyl peptide-induced cholangitis in rat liver. Liver 19:253–258
Numata Y, Tazuma S, Nishioka T, Ueno Y, Chayama K (2004) Immune response in mouse experimental cholangitis associated with colitis induced by dextran sulfate sodium. J Gastroenterol Hepatol 19:910–915
Tjandra K, Le T, Swain MG (2002) Experimental colitis attenuates development of toxin-induced cholangitis in rats. Dig Dis Sci 47:1216–1223
Nonomura A, Kono N, Minato H (1998) Nakanuma Y (1998) Diffuse biliary tract involvement mimicking primary sclerosing cholangitis in an experimental model of chronic graft-versus-host disease in mice. Pathol Int 48:421–427
Orth T, Neurath M, Schirmacher P, Treichel U, Meyer zum Büschenfelde KH, Mayet W (1999) Anti-neutrophil cytoplasmic antibodies in a rat model of trinitrobenzenesulphonic acid-induced liver injury. Eur J Clin Invest 29:929–939
Beaussier M, Wendum D, Fouassier L, Rey C, Barbu V, Lasnier E et al (2005) Adaptative bile duct proliferative response in experimental bile duct ischemia. J Hepatol 42:257–265
Buxbaum J, Qian P, Khuu C, Shneider BL, Daikh DI, Gershwin ME et al (2006) Novel model of antigen-specific induction of bile duct injury. Gastroenterology 131:1899–1906
Seidel D, Eickmeier I, Kühl AA, Hamann A, Loddenkemper C, Schott E (2014) CD8 T cells primed in the gut-associated lymphoid tissue induce immune-mediated cholangitis in mice. Hepatology 59:601–611
Ernst TM, Schwinge D, Raabe N, Daubmann A, Kaul MG, Adam G, et al (2014) Imaging of the murine biliopancreatic tract at 7 tesla: technique and results in a model of primary sclerosing cholangitis. J Magn Reson Imaging. doi:10.1002/jmri.24475
Smit JJ, Schinkel AH, Oude Elferink RP, Groen AK, Wagenaar E, van Deemter L et al (1993) Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75:451–462
Halilbasic E, Fiorotto R, Fickert P, Marschall HU, Moustafa T, Spirli C et al (2009) Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2−/− mice. Hepatology 49:1972–1981
Baghdasaryan A, Claudel T, Kosters A, Gumhold J, Silbert D, Thüringer A et al (2010) Curcumin improves sclerosing cholangitis in Mdr2−/− mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation. Gut 59:521–530
Baghdasaryan A, Claudel T, Gumhold J, Silbert D, Adorini L, Roda A et al (2011) Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2−/− (Abcb4−/−) mouse cholangiopathy model by promoting biliary HCO−3 output. Hepatology 54:1303–1312
Moustafa T, Fickert P, Magnes C, Guelly C, Thueringer A, Frank S et al (2012) Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury. Gastroenterology 142:140–151
Ehlken H, Kondylis V, Heinrichsdorff J, Ochoa-Callejero L, Roskams T, Pasparakis M (2011) Hepatocyte IKK2 protects Mdr2−/− mice from chronic liver failure. PLoS One 6:e25942
Barikbin R, Neureiter D, Wirth J, Erhardt A, Schwinge D, Kluwe J et al (2012) Induction of heme oxygenase 1 prevents progression of liver fibrosis in Mdr2 knockout mice. Hepatology 55:553–562
Strack I, Schulte S, Varnholt H, Schievenbusch S, Töx U, Wendland K et al (2011) β-Adrenoceptor blockade in sclerosing cholangitis of Mdr2 knockout mice: antifibrotic effects in a model of nonsinusoidal fibrosis. Lab Invest 91:252–261
Blaas L, Kornfeld JW, Schramek D, Musteanu M, Zollner G, Gumhold J et al (2010) Disruption of the growth hormone–signal transducer and activator of transcription 5–insulinlike growth factor 1 axis severely aggravates liver fibrosis in a mouse model of cholestasis. Hepatology 51:1319–1326
Trauner M, Fickert P, Wagner M (2007) MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. Semin Liver Dis 27:77–98
Henckaerts L, Jaspers M, Van Steenbergen W, Vliegen L, Fevery J, Nuytten H et al (2009) Cystic fibrosis transmembrane conductance regulator gene polymorphisms in patients with primary sclerosing cholangitis. J Hepatol 50:150–157
Snouwaert JN, Brigman KK, Latour AM, Malouf NN, Boucher RC, Smithies O et al (1992) An animal model for cystic fibrosis made by gene targeting. Science 257:1083–1088
Dorin JR, Dickinson P, Alton EW, Smith SN, Geddes DM, Stevenson BJ et al (1992) Cystic fibrosis in the mouse by targeted insertional mutagenesis. Nature 359:211–215
Barrett JC, Clayton DG, Concannon P, Akolkar B, Cooper JD, Erlich HA et al (2009) Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 41:703–707
Zeiher BG, Eichwald E, Zabner J, Smith JJ, Puga AP, McCray PB Jr et al (1995) A mouse model for the delta F508 allele of cystic fibrosis. J Clin Invest 96:2051–2064
Lyoumi S, Abitbol M, Rainteau D, Karim Z, Bernex F, Oustric V et al (2011) Protoporphyrin retention in hepatocytes and Kupffer cells prevents sclerosing cholangitis in erythropoietic protoporphyria mouse model. Gastroenterology 141:1509–1519
Fickert P (2014) Time to say goodbye to the drug or the model?—why do drugs fail to live up to their promise in bile duct ligated mice? J Hepatol 60:12–15
Colledge WH, Abella BS, Southern KW, Ratcliff R, Jiang C, Cheng SH et al (1995) Generation and characterization of a delta F508 cystic fibrosis mouse model. Nat Genet 10:445–452
Lichtman SN, Keku J, Schwab JH, Sartor RB (1991) Evidence for peptidoglycan absorption in rats with experimental small bowel bacterial overgrowth. Infect Immun 59:555–562
Lichtman SN, Sartor RB (1991) Duct proliferation following biliary obstruction in the rat. Gastroenterology 100:1785–1787
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pollheimer, M.J., Fickert, P. Animal Models in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Clinic Rev Allerg Immunol 48, 207–217 (2015). https://doi.org/10.1007/s12016-014-8442-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12016-014-8442-y